Purpose of reviewJAK2 inhibitors have changed the therapeutic strategies for the management of primary and secondary myelofibrosis. Ruxolitinib, the first available agent, improved disease-related symptoms, spleen volume, and overall survival compared to conventional chemotherapy. It has been revealed that after 3 years of treatment, about 50% of patients discontinued ruxolitinib for resistance and/or intolerance and should be candidate to a second line of treatment.Recent findingsSecond-generation tyrosine kinase inhibitors have been tested in this setting, but all these new drugs do not significantly impact on disease progression. Novel agents are in developments that target on different pathways, alone or in combination with JAK2 inhibitors.SummaryIn this review, we summarize all the clinical efficacy and safety data of these drugs providing a vision of the possible future.
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors / Breccia, Massimo; Assanto, Giovanni Manfredi; Laganà, Alessandro; Scalzulli, Emilia; Martelli, Maurizio. - In: CURRENT OPINION IN ONCOLOGY. - ISSN 1040-8746. - 34:6(2022), pp. 729-737. [10.1097/CCO.0000000000000898]
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors
Breccia, Massimo;Assanto, Giovanni Manfredi;Scalzulli, Emilia;Martelli, Maurizio
2022
Abstract
Purpose of reviewJAK2 inhibitors have changed the therapeutic strategies for the management of primary and secondary myelofibrosis. Ruxolitinib, the first available agent, improved disease-related symptoms, spleen volume, and overall survival compared to conventional chemotherapy. It has been revealed that after 3 years of treatment, about 50% of patients discontinued ruxolitinib for resistance and/or intolerance and should be candidate to a second line of treatment.Recent findingsSecond-generation tyrosine kinase inhibitors have been tested in this setting, but all these new drugs do not significantly impact on disease progression. Novel agents are in developments that target on different pathways, alone or in combination with JAK2 inhibitors.SummaryIn this review, we summarize all the clinical efficacy and safety data of these drugs providing a vision of the possible future.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
